309 related articles for article (PubMed ID: 7520604)
1. Treatment of murine lupus with CTLA4Ig.
Finck BK; Linsley PS; Wofsy D
Science; 1994 Aug; 265(5176):1225-7. PubMed ID: 7520604
[TBL] [Abstract][Full Text] [Related]
2. CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley PS; Brady W; Urnes M; Grosmaire LS; Damle NK; Ledbetter JA
J Exp Med; 1991 Sep; 174(3):561-9. PubMed ID: 1714933
[TBL] [Abstract][Full Text] [Related]
3. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus.
Mihara M; Tan I; Chuzhin Y; Reddy B; Budhai L; Holzer A; Gu Y; Davidson A
J Clin Invest; 2000 Jul; 106(1):91-101. PubMed ID: 10880052
[TBL] [Abstract][Full Text] [Related]
4. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice.
Freeman GJ; Borriello F; Hodes RJ; Reiser H; Hathcock KS; Laszlo G; McKnight AJ; Kim J; Du L; Lombard DB
Science; 1993 Nov; 262(5135):907-9. PubMed ID: 7694362
[TBL] [Abstract][Full Text] [Related]
5. Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor.
Razi-Wolf Z; Galvin F; Gray G; Reiser H
Proc Natl Acad Sci U S A; 1993 Dec; 90(23):11182-6. PubMed ID: 7504299
[TBL] [Abstract][Full Text] [Related]
6. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.
Peach RJ; Bajorath J; Brady W; Leytze G; Greene J; Naemura J; Linsley PS
J Exp Med; 1994 Dec; 180(6):2049-58. PubMed ID: 7964482
[TBL] [Abstract][Full Text] [Related]
7. Expression and functional significance of an additional ligand for CTLA-4.
Lenschow DJ; Su GH; Zuckerman LA; Nabavi N; Jellis CL; Gray GS; Miller J; Bluestone JA
Proc Natl Acad Sci U S A; 1993 Dec; 90(23):11054-8. PubMed ID: 7504292
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus.
Wang X; Huang W; Mihara M; Sinha J; Davidson A
J Immunol; 2002 Feb; 168(4):2046-53. PubMed ID: 11823542
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule.
Linsley PS; Wallace PM; Johnson J; Gibson MG; Greene JL; Ledbetter JA; Singh C; Tepper MA
Science; 1992 Aug; 257(5071):792-5. PubMed ID: 1496399
[TBL] [Abstract][Full Text] [Related]
10. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation.
Hathcock KS; Laszlo G; Dickler HB; Bradshaw J; Linsley P; Hodes RJ
Science; 1993 Nov; 262(5135):905-7. PubMed ID: 7694361
[TBL] [Abstract][Full Text] [Related]
11. Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation.
Boussiotis VA; Freeman GJ; Gribben JG; Daley J; Gray G; Nadler LM
Proc Natl Acad Sci U S A; 1993 Dec; 90(23):11059-63. PubMed ID: 7504293
[TBL] [Abstract][Full Text] [Related]
12. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.
Liu Z; Geboes K; Hellings P; Maerten P; Heremans H; Vandenberghe P; Boon L; van Kooten P; Rutgeerts P; Ceuppens JL
J Immunol; 2001 Aug; 167(3):1830-8. PubMed ID: 11466409
[TBL] [Abstract][Full Text] [Related]
13. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation.
Cross AH; Girard TJ; Giacoletto KS; Evans RJ; Keeling RM; Lin RF; Trotter JL; Karr RW
J Clin Invest; 1995 Jun; 95(6):2783-9. PubMed ID: 7539461
[TBL] [Abstract][Full Text] [Related]
14. Treatment of autoimmunity by inhibition of T cell costimulation.
Daikh DI; Wofsy D
Adv Exp Med Biol; 2001; 490():113-7. PubMed ID: 11505969
[No Abstract] [Full Text] [Related]
15. New protein steals the show as 'costimulator' of T cells.
Cohen J
Science; 1993 Nov; 262(5135):844-5. PubMed ID: 7694360
[No Abstract] [Full Text] [Related]
16. Defective B7 expression on antigen-presenting cells underlying T cell activation abnormalities in systemic lupus erythematosus (SLE) patients.
García-Cózar FJ; Molina IJ; Cuadrado MJ; Marubayashi M; Peña J; Santamaría M
Clin Exp Immunol; 1996 Apr; 104(1):72-9. PubMed ID: 8603537
[TBL] [Abstract][Full Text] [Related]
17. Prevention of lupus nephritis development in NZB/NZW mice by selective blockade of CD28.
Laurent L; Le Fur A; Bloas RL; Néel M; Mary C; Moreau A; Poirier N; Vanhove B; Fakhouri F
Eur J Immunol; 2017 Aug; 47(8):1368-1376. PubMed ID: 28631301
[TBL] [Abstract][Full Text] [Related]
18. B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses.
Zhang YQ; Joost van Neerven RJ; Van Gool SW; Coorevits L; de Boer M; Ceuppens JL
Int Immunol; 1997 Aug; 9(8):1095-102. PubMed ID: 9263006
[TBL] [Abstract][Full Text] [Related]
19. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement.
Perez VL; Van Parijs L; Biuckians A; Zheng XX; Strom TB; Abbas AK
Immunity; 1997 Apr; 6(4):411-7. PubMed ID: 9133420
[TBL] [Abstract][Full Text] [Related]
20. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.
Freeman GJ; Gribben JG; Boussiotis VA; Ng JW; Restivo VA; Lombard LA; Gray GS; Nadler LM
Science; 1993 Nov; 262(5135):909-11. PubMed ID: 7694363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
